logo-loader
viewNu Skin Enterprises, Inc.

Nu Skin shares tank as it misses fourth quarter hopes

Earnings per share for the quarter were $0.62, compared to$0.77 in the prior-year period.

rsz_shutterstock_239285224.jpg
ageLOC are anti-aging products from Nu Skin

Shares in Nu Skin Enterprises (NYSE:NUS) plummeted in early deals as it released fourth quarter results that missed expectations.

Revenue was $572.2mln, compared to $609.6mln in the same period the previous year, with around $42mln being hit by foreign currency fluctuations.

Earnings per share for the quarter were $0.62, compared to$0.77 in the prior-year period.

The company also reported full-year 2015 revenue of $2.25 billion, compared to $2.57 billion in 2014, with the strong US dollar adversely hitting the company’s figures by around 8%.

Shares in the firm, have dropped by more than a third this year, and were 21% lower to US$24.72 in early deals.

Truman Hunt, president and chief executive officer, said: “We generated sequential business improvement in the fourth quarter as we continued introducing our newest ageLOC products.”

The launch of ageLOC was particularly strong in Asia, especially in Japan and South Korea, with the company seeing a high level of follow-on purchases in the first quarter, it said.

"As we introduce our new products throughout the year, the key to our success will be our ability to generate growth in sales leaders and a corresponding increase in actives,” Hunt added.

Quick facts: Nu Skin Enterprises, Inc.

Price: 38.88 USD

NYSE:NUS
Market: NYSE
Market Cap: $2.16 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioLargo CEO 'proud, but not satisfied' as revenue climbs in...

BioLargo Inc (OTCMKTS:BLGO) CEO Dennis Calvert tells Proactive he is 'proud, but not satisfied' with 3Q revenue that soared 93% year-over-year on the back of the company’s Odor-No-More and BioLargo Engineering divisions. Among 3Q highlights, Calvert says its engineering division has become...

1 hour, 13 minutes ago

2 min read